ArticleBrazilian journal of microbiology : [publication of the Brazilian Society for Microbiology]2026
Whole genome-sequence-based molecular characterisation of Salmonella Kentucky co-resistant to fluoroquinolones and cephalosporins isolated from children during 2017 to 2024: emergence of bla
Article in Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology], 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Epidemiology, resistance profiles, and molecular characteristics of pediatric salmonella isolates: prevalence of a clonalFrontiers in cellular and infection microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Salmonella Kentucky has become a global concern due to its invasiveness and rapid increase in antimicrobial resistance. It is an emerging human pathogen which has surfaced as a multidrug-resistant (MDR) clone, jeopardizing public’s health. Here, we have focused on the molecular characterisation of S. Kentucky isolated from clinical samples of children in India. S. Kentucky, isolated from the clinical samples of children from different hospitals in India during March 2017 to February 2024 were sent to the Gastro-Intestinal Tract Pathogen Repository of the ICMR-National Institute of Research in Bacterial Infections (NIRBI) for confirmation by serotyping. After confirmation, the isolates were investigated for antimicrobial susceptibility, antimicrobial resistance genes (ARGs), plasmid profiling, multilocus sequence typing (MLST) & pulsed-field gel electrophoresis (PFGE) subtypes. Whole genome sequencing (WGS) was performed for representative MDR S. Kentucky isolates. Among the 45 S. Kentucky isolates, higher resistance rates of 97.77%, 93.3%, 86.7%, 77.8% and 64.44% were observed for ciprofloxacin, ampicillin, tetracycline, norfloxacin and 3rd generation cephalosporins respectively. All isolates were susceptible to chloramphenicol and carbapenems. WGS revealed the presence of ESBL genes, blaCTX−M−55, blaCTX−M−15, blaOXA−9 and multiple ARGs. Fluoroquinolone resistance was linked to mutations in gyrA (Ser83→Phe, Asp87→Tyr, ) and parC (Ser80→Iso) genes. Conjugative plasmid IncC and IncX4 harboring blaCTX−M−15 and blaCTX−M−55 respectively, were found in the study isolates. ST198 (n = 44) was found to be the predominant genotype by MLST. PFGE showed heterogeneous S. Kentucky strains in circulation. MDR S. Kentucky poses a potential health risk to the general public and alerts for the necessity of improved monitoring and investigation of this serovar by public health and food safety authorities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.